Last reviewed · How we verify

Choriongonadotropin

Ferring Pharmaceuticals · FDA-approved active Small molecule Quality 2/100

Choriongonadotropin is a Small molecule drug developed by Ferring Pharmaceuticals. It is currently FDA-approved. Also known as: Brevactid®, human chorionic gonadotropin (hCG).

At a glance

Generic nameChoriongonadotropin
Also known asBrevactid®, human chorionic gonadotropin (hCG)
SponsorFerring Pharmaceuticals
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Choriongonadotropin

What is Choriongonadotropin?

Choriongonadotropin is a Small molecule drug developed by Ferring Pharmaceuticals.

Who makes Choriongonadotropin?

Choriongonadotropin is developed and marketed by Ferring Pharmaceuticals (see full Ferring Pharmaceuticals pipeline at /company/ferring).

Is Choriongonadotropin also known as anything else?

Choriongonadotropin is also known as Brevactid®, human chorionic gonadotropin (hCG).

What development phase is Choriongonadotropin in?

Choriongonadotropin is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing